Gubra (GUBRA) Aktievy
Gubra A/S är ett bioteknikföretag som fokuserar på preklinisk kontraktsforskning och peptidbaserad läkemedelsutveckling inom metabola och fibrotiska sjukdomar i Europa, Nordamerika och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
GUBRA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gubra A/S Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | DKK 326.80 |
| 52 veckors högsta | DKK 557.50 |
| 52 veckors lägsta | DKK 293.00 |
| Beta | 0.27 |
| 1 månads förändring | -3.60% |
| 3 månaders förändring | -10.27% |
| 1 års förändring | -25.93% |
| 3 års förändring | 255.29% |
| 5 års förändring | n/a |
| Förändring sedan börsintroduktionen | 197.09% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 24
GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.Uppdatering av berättelse • Jun 10
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.Uppdatering av berättelse • May 26
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Recent updates
Uppdatering av berättelse • Jun 24
GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.Uppdatering av berättelse • Jun 10
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.Uppdatering av berättelse • May 26
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analysartikel • May 14
Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...Uppdatering av berättelse • Apr 27
GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).Uppdatering av berättelse • Apr 12
GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).Uppdatering av berättelse • Mar 29
GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).Uppdatering av berättelse • Mar 15
GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.Uppdatering av berättelse • Mar 01
GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).Uppdatering av berättelse • Aug 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.Analysartikel • Jun 28
Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...Ny berättelse • May 16
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.Analysartikel • May 04
We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysartikel • Mar 11
Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...Analysartikel • Jan 14
We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Jun 19
Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...Analysartikel • Mar 07
Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...Aktieägarnas avkastning
| GUBRA | DK Life Sciences | DK Marknad | |
|---|---|---|---|
| 7D | -2.7% | 7.0% | 1.0% |
| 1Y | -25.9% | -3.8% | -11.5% |
Avkastning vs industri: GUBRA presterade sämre än Danish Life Sciences branschen som gav -3.8 % under det senaste året.
Avkastning vs Marknaden: GUBRA presterade sämre än Danish marknaden som gav -11.5 % under det senaste året.
Prisvolatilitet
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DK Market | 8.0% |
| 10% least volatile stocks in DK Market | 2.5% |
Stabil aktiekurs: GUBRA s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för Danish.
Volatilitet över tid: GUBRA s veckovolatilitet ( 6% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av Danish aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2008 | 300 | Markus Rohrwild | www.gubra.dk |
Gubra A/S är ett bioteknikföretag som fokuserar på preklinisk kontraktsforskning och peptidbaserad läkemedelsutveckling inom metabola och fibrotiska sjukdomar i Europa, Nordamerika och internationellt. Bolaget bedriver verksamhet genom tre segment: Preklinisk kontraktsforskning (CRO), Discovery & Partnerships samt Gubra Green. Bolaget erbjuder preklinisk kontraktsforskning och utvecklingstjänster inom metabola och fibrotiska sjukdomar för läkemedels- och bioteknikindustrin, samt tillhandahåller tjänster inom in vivo-farmakologi, biomarköranalyser, bioinformatik, next gen-sekvensering, farmakokinetik samt 2D- och 3D-histologi med artificiell intelligenspatologi.
Gubra A/S Sammanfattning av grunderna
| GUBRA grundläggande statistik | |
|---|---|
| Börsvärde | DKK 5.26b |
| Vinst(TTM) | DKK 1.69b |
| Intäkter(TTM) | DKK 2.64b |
3.2x
P/E-förhållande2.0x
P/S-förhållandeÄr GUBRA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| GUBRA resultaträkning (TTM) | |
|---|---|
| Intäkter | DKK 2.64b |
| Kostnad för intäkter | DKK 80.08m |
| Bruttovinst | DKK 2.56b |
| Övriga kostnader | DKK 866.16m |
| Intäkter | DKK 1.69b |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
Aug 20, 2026
| Vinst per aktie (EPS) | 103.51 |
| Bruttomarginal | 96.96% |
| Nettovinstmarginal | 64.11% |
| Skuld/egenkapitalförhållande | 0% |
Hur har GUBRA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/01 19:34 |
| Aktiekurs vid dagens slut | 2026/07/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Gubra A/S bevakas av 3 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |